As HGK is able to inhibit the tumor growth of TKI-resistant NSCLC cells (Figure 1 and Figure 4), the potential inclusion of HGK as an adjuvant drug in the treatment of NSCLC patients harboring activating EGFR mutations might be explored. The gene discussed is MAP4K4; the disease is non-small cell lung carcinoma.